Le Lézard
Classified in: Health, Science and technology
Subjects: MISCELLANEOUS, MISCELLANEOUS

Information on the total number of voting rights and shares



REGULATED INFORMATION

Information on the total number of voting rights and shares

Mont-Saint-Guibert (Belgium), November 26, 2021, 10:30 pm CET / 4:30 pm ET ? In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the belowinformation following the exercise of subscription rights and the issue of new shares.

*

*        *

For further information, please contact:

Nyxoah
Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com
+1 917 749 1494

Gilmartin Group
Vivian Cervantes
IR@nyxoah.com


Attachment



These press releases may also interest you

at 00:23
Based on its recent analysis of the global artificial intelligence (AI)-enabled drug discovery industry, Frost & Sullivan recognizes Insilico Medicine...

24 jan 2022
The kidney stones market potential growth difference will be USD 416.09 million from 2021 to 2026, as per the latest market analysis report by Technavio. The market is likely to witness an accelerating momentum at a CAGR of 6.69% during this period....

24 jan 2022
This week, the Foundation for Government Accountability (FGA) released data showing how Medicaid program mismanagement, federal restrictions, and Medicaid expansion have led to significant increases in improper payment rates. With a record-high 89...

24 jan 2022
Yosi Health, a provider of digital patient scheduling, registration, payment, and communication cloud-based software solutions, announced today they have added Hants Williams, PhD, RN, a professor at the State University of New York (SUNY) at Stony...

24 jan 2022
RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, recently announced positive results from the completion of its Phase II trial in China for Telitacicept in the treatment of primary Sjögren's syndrome ("pSS"). A total of 42...

24 jan 2022
Demonstrating innovation leadership on a global level, ImmVira announced that, its custom-designed new-generation oncolytic herpes simplex virus ("oHSV") vector enabling CAR-T treatment for solid tumors has started pilot-scale manufacturing and...



News published on 26 november 2021 at 16:30 and distributed by: